<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02872753</url>
  </required_header>
  <id_info>
    <org_study_id>ACP-MEN</org_study_id>
    <nct_id>NCT02872753</nct_id>
  </id_info>
  <brief_title>Intra-operative Injection of Autologous Conditioned Plasma (ACP) Following Partial Meniscectomy</brief_title>
  <acronym>ACP-MEN</acronym>
  <official_title>Intra-operative ACP Injection Following Partial Meniscectomy: a Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Istituto Ortopedico Rizzoli</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Istituto Ortopedico Rizzoli</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the present double blind controlled study is to evaluate the effects in terms of
      pain control and functional recovery provided by a single intra-operative injection of ACP
      performed at the end of arthroscopic partial meniscectomy.

      Patients included in this trial will be randomized in two treatment groups: the first one
      will receive a single injection of 3-5 cc of ACP (using a dedicated centrifuge) at the end of
      the arthroscopic meniscectomy, whereas the second group will be treated by surgery alone. In
      order to ensure the double blinding of the trial all the patients enrolled will undergo blood
      harvesting before anesthesia, and acp will be produced just for the patients included in ACP
      group.

      All patients will be evaluated basally, and then at 15, 30, 60, and 180 days after surgery by
      the following evaluation tools: IKDC (International Knee Documentation Committee) subjective,
      VAS (Visual Analogue Score) for pain, EQ-VAS for general Health Status, KOOS (Knee Injury and
      Osteoarthritis Outcome Score) and Tegner score. Furthermore, during the basal evaluation and
      at each follow-up visit up to 2 months, active and passive Range of Motion (ROM) of both the
      operated and contralateral knee were documented; also in addition, the trans-patellar
      circumference of both knees was registered to assess the trend of knee swelling over time.

      Drugs assumption during the follow-up period will be recorded for each patient. All eventual
      adverse events occurred during the follow-up period will be registered.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 16, 2017</start_date>
  <completion_date type="Anticipated">March 2021</completion_date>
  <primary_completion_date type="Anticipated">November 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in IKDC (International Knee Documentation Committee) score over the various follow-up times</measure>
    <time_frame>basal, 15,30,60,180 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in VAS( Visual Analogue score) for pain over the various follow-up times</measure>
    <time_frame>basal, 15,30,60,180 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in KOOS (Knee Injury and Osteoarthritis Outcome Score) over the various follow-up times</measure>
    <time_frame>basal, 15,30,60,180 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Tegner Score over the various follow-up times</measure>
    <time_frame>basal, 30,60,180 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in transpatellar circumference over time</measure>
    <time_frame>basal, 15,30,60,180 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in active and passive ROM</measure>
    <time_frame>basal, 15,30,60,180 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events report</measure>
    <time_frame>15 days after surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events report</measure>
    <time_frame>30 days after surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events report</measure>
    <time_frame>60 days after surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events report</measure>
    <time_frame>180 days after surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in VAS for general health status</measure>
    <time_frame>basal, 30,60,180 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Meniscectomy</condition>
  <arm_group>
    <arm_group_label>ACP GROUP</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive a single intra-op ACP injection following a procedure of arthroscopic partial meniscectomy (medial or lateral)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CONTROL GROUP</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Patients will be treated by standard meniscectomy alone (medial or lateral)</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>ACP</intervention_name>
    <description>Autologous Conditioned Plasma will be obtained directly in the operatory room from the peripheral venous blood of the patient, and injected intra-articularly at the end of arthroscopic meniscectomy</description>
    <arm_group_label>ACP GROUP</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Standard Meniscectomy</intervention_name>
    <description>Patients will receive standard arthroscopic meniscectomy</description>
    <arm_group_label>CONTROL GROUP</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  chronic symptomatic meniscal tears requiring partial resection;

          -  healthy contra-lateral knee (i.e. no pain or functional limitation in the
             contra-lateral joint);

        Exclusion Criteria:

          -  meniscal lesions requiring suture;

          -  previous surgery on the index knee;

          -  other concurrent articular lesion requiring surgical treatment (e.g.: cartilage or
             ligament injuries);

          -  history of knee infectious arthritis;

          -  concurrent rheumatic, metabolic or severe systemic disease;

          -  Body Mass Index (BMI) &gt; 30;

          -  known hypersensibility or allergy to/towards HA ;

          -  alcohol or other substances abuse/excess.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alessandro Di Martino, MD</last_name>
    <role>Study Director</role>
    <affiliation>Nano-biotechnology Lab, Rizzoli Orthopaedic Institute, Bologna, Italy</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Giuseppe Filardo, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Biomechanics Lab, Rizzoli Orthopaedic Institute, Bologna, Italy</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Berardo Di Matteo, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Biomechanics Lab, Rizzoli Orthopaedic Institute, Bologna, Italy</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Alessandro Di Martino, MD</last_name>
    <phone>+39 0516366567</phone>
    <email>a.dimartino@biomec.ior.it</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Giuseppe Filardo, MD</last_name>
    <phone>+39 0516366567</phone>
    <email>g.filardo@biomec.ior.it</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Rizzoli Orthopaedic Institute</name>
      <address>
        <city>Bologna</city>
        <zip>40136</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Filardo Giuseppe, MD</last_name>
      <phone>+390516366567</phone>
      <email>g.filardo@biomec.ior.it</email>
    </contact>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <reference>
    <citation>Abrams GD, Frank RM, Gupta AK, Harris JD, McCormick FM, Cole BJ. Trends in meniscus repair and meniscectomy in the United States, 2005-2011. Am J Sports Med. 2013 Oct;41(10):2333-9. doi: 10.1177/0363546513495641. Epub 2013 Jul 17.</citation>
    <PMID>23863849</PMID>
  </reference>
  <reference>
    <citation>Filardo G, Di Matteo B, Di Martino A, Merli ML, Cenacchi A, Fornasari P, Marcacci M, Kon E. Platelet-Rich Plasma Intra-articular Knee Injections Show No Superiority Versus Viscosupplementation: A Randomized Controlled Trial. Am J Sports Med. 2015 Jul;43(7):1575-82. doi: 10.1177/0363546515582027. Epub 2015 May 7.</citation>
    <PMID>25952818</PMID>
  </reference>
  <reference>
    <citation>Heard BJ, Barton KI, Chung M, Achari Y, Shrive NG, Frank CB, Hart DA. Single intra-articular dexamethasone injection immediately post-surgery in a rabbit model mitigates early inflammatory responses and post-traumatic osteoarthritis-like alterations. J Orthop Res. 2015 Dec;33(12):1826-34. doi: 10.1002/jor.22972. Epub 2015 Jul 7.</citation>
    <PMID>26135713</PMID>
  </reference>
  <reference>
    <citation>Thein R, Haviv B, Kidron A, Bronak S. Intra-articular injection of hyaluronic acid following arthroscopic partial meniscectomy of the knee. Orthopedics. 2010 Oct 11;33(10):724. doi: 10.3928/01477447-20100826-11.</citation>
    <PMID>20954664</PMID>
  </reference>
  <reference>
    <citation>Filardo G, Kon E, Roffi A, Di Matteo B, Merli ML, Marcacci M. Platelet-rich plasma: why intra-articular? A systematic review of preclinical studies and clinical evidence on PRP for joint degeneration. Knee Surg Sports Traumatol Arthrosc. 2015 Sep;23(9):2459-74. doi: 10.1007/s00167-013-2743-1. Epub 2013 Nov 26. Review.</citation>
    <PMID>24275957</PMID>
  </reference>
  <reference>
    <citation>Andia I, Maffulli N. Platelet-rich plasma for managing pain and inflammation in osteoarthritis. Nat Rev Rheumatol. 2013 Dec;9(12):721-30. doi: 10.1038/nrrheum.2013.141. Epub 2013 Oct 1. Review.</citation>
    <PMID>24080861</PMID>
  </reference>
  <reference>
    <citation>Boswell SG, Cole BJ, Sundman EA, Karas V, Fortier LA. Platelet-rich plasma: a milieu of bioactive factors. Arthroscopy. 2012 Mar;28(3):429-39. doi: 10.1016/j.arthro.2011.10.018. Epub 2012 Jan 28.</citation>
    <PMID>22284405</PMID>
  </reference>
  <reference>
    <citation>Lee HR, Shon OJ, Park SI, Kim HJ, Kim S, Ahn MW, Do SH. Platelet-Rich Plasma Increases the Levels of Catabolic Molecules and Cellular Dedifferentiation in the Meniscus of a Rabbit Model. Int J Mol Sci. 2016 Jan 16;17(1). pii: E120. doi: 10.3390/ijms17010120.</citation>
    <PMID>26784189</PMID>
  </reference>
  <reference>
    <citation>Blanke F, Vavken P, Haenle M, von Wehren L, Pagenstert G, Majewski M. Percutaneous injections of Platelet rich plasma for treatment of intrasubstance meniscal lesions. Muscles Ligaments Tendons J. 2015 Oct 20;5(3):162-6. doi: 10.11138/mltj/2015.5.3.162. eCollection 2015 Jul-Sep.</citation>
    <PMID>26605189</PMID>
  </reference>
  <reference>
    <citation>Pujol N, Salle De Chou E, Boisrenoult P, Beaufils P. Platelet-rich plasma for open meniscal repair in young patients: any benefit? Knee Surg Sports Traumatol Arthrosc. 2015 Jan;23(1):51-8. doi: 10.1007/s00167-014-3417-3. Epub 2014 Nov 7.</citation>
    <PMID>25377191</PMID>
  </reference>
  <reference>
    <citation>Griffin JW, Hadeed MM, Werner BC, Diduch DR, Carson EW, Miller MD. Platelet-rich plasma in meniscal repair: does augmentation improve surgical outcomes? Clin Orthop Relat Res. 2015 May;473(5):1665-72. doi: 10.1007/s11999-015-4170-8. Epub 2015 Feb 6.</citation>
    <PMID>25663423</PMID>
  </reference>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 16, 2016</study_first_submitted>
  <study_first_submitted_qc>August 16, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 19, 2016</study_first_posted>
  <last_update_submitted>September 12, 2017</last_update_submitted>
  <last_update_submitted_qc>September 12, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 13, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Istituto Ortopedico Rizzoli</investigator_affiliation>
    <investigator_full_name>Federica Balboni</investigator_full_name>
    <investigator_title>BScD</investigator_title>
  </responsible_party>
  <keyword>Autologous Conditioned Plasma</keyword>
  <keyword>meniscectomy</keyword>
  <keyword>randomized controlled trial</keyword>
  <keyword>intra-op injection</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

